The Food and Drug Administration (FDA) requires a new drug’s manufacturer to present affirmative evidence of its efficacy and safety before it can be marketed. Because testing new drugs requires a delay between identification of an important, novel prescription
Read More...
Read the complete post at http://healthaffairs.org/blog/2016/06/23/four-ways-to-address-the-ethical-tensions-around-expedited-approval-of-new-prescription-drugs/
Posted
Jun 23 2016, 08:00 AM
by
Health Affairs BlogHealth Affairs Blog
Filed under: Public Health, Bioethics, Quality, Population Health, Featured, Drugs and Medical Technology, FDA, Drug approval, priority review, Risk Evaluation and Mitigation Strategies, breakthrough drugs